BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36107485)

  • 1. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study.
    de Castro Silva I; Bianchi A; Deshpande NU; Sharma P; Mehra S; Garrido VT; Saigh SJ; England J; Hosein PJ; Kwon D; Merchant NB; Datta J
    Elife; 2022 Sep; 11():. PubMed ID: 36107485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
    Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
    Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer.
    Bianchi A; De Castro Silva I; Deshpande NU; Singh S; Mehra S; Garrido VT; Guo X; Nivelo LA; Kolonias DS; Saigh SJ; Wieder E; Rafie CI; Dosch AR; Zhou Z; Umland O; Amirian H; Ogobuiro IC; Zhang J; Ban Y; Shiau C; Nagathihalli NS; Montgomery EA; Hwang WL; Brambilla R; Komanduri K; Villarino AV; Toska E; Stanger BZ; Gabrilovich DI; Merchant NB; Datta J
    Cancer Discov; 2023 Jun; 13(6):1428-1453. PubMed ID: 36946782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
    Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
    Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
    Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
    J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance.
    Ajina R; Malchiodi ZX; Fitzgerald AA; Zuo A; Wang S; Moussa M; Cooper CJ; Shen Y; Johnson QR; Parks JM; Smith JC; Catalfamo M; Fertig EJ; Jablonski SA; Weiner LM
    Cancer Immunol Res; 2021 Apr; 9(4):386-400. PubMed ID: 33509790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.
    Ijichi H; Chytil A; Gorska AE; Aakre ME; Fujitani Y; Fujitani S; Wright CV; Moses HL
    Genes Dev; 2006 Nov; 20(22):3147-60. PubMed ID: 17114585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Strong JS; Vos EL; Mcintyre CA; Chou JF; Gonen M; Tang LH; Soares KC; Balachandran VP; Kingham TP; D'Angelica MI; Jarnagin WR; Drebin J; Kunstman JW; Allen PJ; Wei AC
    Am Surg; 2022 Jun; 88(6):1153-1158. PubMed ID: 33517697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
    Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
    Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Black raspberries suppress pancreatic cancer through modulation of NKp46
    Pan P; Zhu Z; Oshima K; Aldakkak M; Tsai S; Huang YW; Dong W; Zhang J; Lin CW; Wang Y; Yearsley M; Yu J; Wang LS
    Food Front; 2020 Mar; 1(1):70-82. PubMed ID: 32368735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients.
    Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
    Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
    Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
    Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
    Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
    Hosein AN; Dangol G; Okumura T; Roszik J; Rajapakshe K; Siemann M; Zaid M; Ghosh B; Monberg M; Guerrero PA; Singhi A; Haymaker CL; Clevers H; Abou-Elkacem L; Woermann SM; Maitra A
    Gastroenterology; 2022 Apr; 162(4):1303-1318.e18. PubMed ID: 34973294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
    Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
    Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.